 David Badesch
Concepts (509)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 115 | 2025 | 1948 | 6.600 |
Why?
| | Antihypertensive Agents | 33 | 2025 | 512 | 2.830 |
Why?
| | Epoprostenol | 23 | 2015 | 132 | 1.790 |
Why?
| | Recombinant Fusion Proteins | 9 | 2025 | 667 | 1.400 |
Why?
| | Vasodilator Agents | 12 | 2015 | 329 | 1.100 |
Why?
| | Vascular Resistance | 11 | 2025 | 368 | 1.020 |
Why?
| | Registries | 22 | 2025 | 2392 | 0.980 |
Why?
| | Familial Primary Pulmonary Hypertension | 17 | 2024 | 196 | 0.960 |
Why?
| | Pulmonary Wedge Pressure | 9 | 2024 | 66 | 0.910 |
Why?
| | Piperazines | 8 | 2014 | 378 | 0.870 |
Why?
| | Sulfones | 7 | 2012 | 127 | 0.860 |
Why?
| | Exercise Tolerance | 21 | 2025 | 282 | 0.850 |
Why?
| | Hemodynamics | 30 | 2024 | 1113 | 0.830 |
Why?
| | Scleroderma, Systemic | 7 | 2021 | 123 | 0.720 |
Why?
| | Connective Tissue Diseases | 5 | 2018 | 84 | 0.700 |
Why?
| | Practice Guidelines as Topic | 7 | 2020 | 1569 | 0.690 |
Why?
| | Exercise Test | 12 | 2025 | 626 | 0.670 |
Why?
| | Sulfonamides | 13 | 2018 | 579 | 0.670 |
Why?
| | Double-Blind Method | 26 | 2025 | 2033 | 0.660 |
Why?
| | Respiratory System Agents | 2 | 2023 | 22 | 0.610 |
Why?
| | Natriuretic Peptide, Brain | 10 | 2025 | 109 | 0.610 |
Why?
| | Phenylpropionates | 5 | 2011 | 27 | 0.610 |
Why?
| | Pulmonary Artery | 14 | 2023 | 1124 | 0.580 |
Why?
| | Pyridazines | 5 | 2011 | 57 | 0.560 |
Why?
| | Adult | 79 | 2025 | 40489 | 0.540 |
Why?
| | Cardiac Catheterization | 13 | 2024 | 557 | 0.540 |
Why?
| | Endothelin Receptor Antagonists | 10 | 2015 | 61 | 0.540 |
Why?
| | Humans | 146 | 2025 | 144667 | 0.510 |
Why?
| | Middle Aged | 81 | 2025 | 35971 | 0.500 |
Why?
| | Activins | 2 | 2025 | 29 | 0.460 |
Why?
| | Treatment Outcome | 34 | 2025 | 11735 | 0.450 |
Why?
| | Pyrimidines | 4 | 2024 | 519 | 0.440 |
Why?
| | Lung Transplantation | 10 | 2025 | 329 | 0.410 |
Why?
| | Disease Management | 6 | 2016 | 650 | 0.410 |
Why?
| | Male | 93 | 2025 | 72431 | 0.400 |
Why?
| | Female | 90 | 2025 | 78304 | 0.390 |
Why?
| | Aged | 44 | 2025 | 25955 | 0.380 |
Why?
| | Risk Assessment | 14 | 2024 | 3729 | 0.370 |
Why?
| | Consensus | 1 | 2014 | 475 | 0.360 |
Why?
| | Thrombosis | 1 | 2016 | 396 | 0.360 |
Why?
| | Anticoagulants | 3 | 2016 | 729 | 0.350 |
Why?
| | Anemia, Sickle Cell | 5 | 2014 | 312 | 0.350 |
Why?
| | Pyrazoles | 3 | 2024 | 512 | 0.330 |
Why?
| | Prognosis | 16 | 2021 | 4312 | 0.330 |
Why?
| | Thinness | 1 | 2011 | 98 | 0.320 |
Why?
| | Prostaglandins | 3 | 2007 | 94 | 0.320 |
Why?
| | Survival Rate | 15 | 2022 | 2089 | 0.310 |
Why?
| | Blood Pressure | 8 | 2014 | 1766 | 0.300 |
Why?
| | Oxygen Consumption | 1 | 2012 | 717 | 0.290 |
Why?
| | Hypertension, Portal | 4 | 2011 | 66 | 0.290 |
Why?
| | Activities of Daily Living | 3 | 2016 | 441 | 0.280 |
Why?
| | Sildenafil Citrate | 8 | 2014 | 60 | 0.280 |
Why?
| | Follow-Up Studies | 18 | 2025 | 5414 | 0.280 |
Why?
| | Coagulants | 1 | 2008 | 19 | 0.280 |
Why?
| | Factor VIIa | 1 | 2008 | 43 | 0.270 |
Why?
| | Lung Neoplasms | 1 | 2021 | 2660 | 0.260 |
Why?
| | Hospitalization | 9 | 2025 | 2446 | 0.260 |
Why?
| | Purines | 8 | 2014 | 187 | 0.260 |
Why?
| | Surveys and Questionnaires | 2 | 2018 | 6041 | 0.250 |
Why?
| | Depressive Disorder | 1 | 2010 | 386 | 0.250 |
Why?
| | Drug Therapy, Combination | 8 | 2025 | 1044 | 0.250 |
Why?
| | Quality of Life | 12 | 2025 | 3183 | 0.250 |
Why?
| | Mixed Connective Tissue Disease | 2 | 2010 | 10 | 0.250 |
Why?
| | Evidence-Based Medicine | 4 | 2019 | 732 | 0.250 |
Why?
| | Health Status | 2 | 2016 | 834 | 0.240 |
Why?
| | Bone Morphogenetic Protein Receptors, Type II | 2 | 2025 | 51 | 0.230 |
Why?
| | Pulmonary Medicine | 3 | 2019 | 78 | 0.230 |
Why?
| | Prospective Studies | 16 | 2021 | 7994 | 0.230 |
Why?
| | Phosphodiesterase 5 Inhibitors | 3 | 2014 | 35 | 0.220 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2012 | 919 | 0.210 |
Why?
| | Hemorrhage | 2 | 2008 | 813 | 0.210 |
Why?
| | Dose-Response Relationship, Drug | 11 | 2021 | 2019 | 0.210 |
Why?
| | Castleman Disease | 1 | 2003 | 16 | 0.200 |
Why?
| | Walk Test | 4 | 2025 | 80 | 0.190 |
Why?
| | Herpesvirus 8, Human | 1 | 2003 | 67 | 0.190 |
Why?
| | DEAE-Dextran | 1 | 2023 | 1 | 0.190 |
Why?
| | Referral and Consultation | 2 | 2025 | 852 | 0.190 |
Why?
| | United States | 21 | 2025 | 16018 | 0.190 |
Why?
| | Muscle, Smooth, Vascular | 6 | 1994 | 441 | 0.190 |
Why?
| | Phosphodiesterase Inhibitors | 4 | 2009 | 72 | 0.180 |
Why?
| | Peptide Fragments | 5 | 2025 | 691 | 0.180 |
Why?
| | Herpesviridae Infections | 1 | 2003 | 149 | 0.180 |
Why?
| | Adolescent | 22 | 2021 | 22409 | 0.180 |
Why?
| | Disease Progression | 6 | 2025 | 2847 | 0.180 |
Why?
| | Body Mass Index | 1 | 2011 | 2419 | 0.180 |
Why?
| | Ventricular Function, Right | 5 | 2009 | 296 | 0.180 |
Why?
| | Biomarkers | 6 | 2021 | 4261 | 0.170 |
Why?
| | Insulin-Like Growth Factor I | 4 | 1994 | 317 | 0.170 |
Why?
| | Lung | 7 | 2019 | 4089 | 0.160 |
Why?
| | Fluid Shifts | 1 | 2020 | 2 | 0.160 |
Why?
| | Medication Adherence | 1 | 2025 | 540 | 0.160 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2021 | 76 | 0.160 |
Why?
| | Severity of Illness Index | 10 | 2024 | 2922 | 0.160 |
Why?
| | Rituximab | 1 | 2021 | 211 | 0.160 |
Why?
| | Exercise Therapy | 1 | 2025 | 475 | 0.160 |
Why?
| | Kaplan-Meier Estimate | 5 | 2025 | 967 | 0.160 |
Why?
| | Methamphetamine | 1 | 2021 | 72 | 0.160 |
Why?
| | Infusions, Intravenous | 7 | 2009 | 422 | 0.160 |
Why?
| | Heart | 2 | 2023 | 626 | 0.160 |
Why?
| | Vasculitis | 2 | 1998 | 69 | 0.160 |
Why?
| | Somatomedins | 2 | 1990 | 28 | 0.150 |
Why?
| | Echocardiography | 4 | 2020 | 644 | 0.150 |
Why?
| | Walking | 8 | 2014 | 542 | 0.150 |
Why?
| | Sodium Chloride | 1 | 2020 | 142 | 0.150 |
Why?
| | Thorax | 1 | 2019 | 51 | 0.150 |
Why?
| | Diagnostic Techniques, Respiratory System | 1 | 2019 | 5 | 0.150 |
Why?
| | Endothelin A Receptor Antagonists | 2 | 2011 | 24 | 0.150 |
Why?
| | HLA-DP alpha-Chains | 1 | 2018 | 4 | 0.150 |
Why?
| | Isoxazoles | 3 | 2008 | 52 | 0.140 |
Why?
| | Immunologic Factors | 1 | 2021 | 259 | 0.140 |
Why?
| | SOXF Transcription Factors | 1 | 2018 | 16 | 0.140 |
Why?
| | Thiophenes | 3 | 2008 | 121 | 0.140 |
Why?
| | HLA-DP beta-Chains | 1 | 2018 | 88 | 0.140 |
Why?
| | Transforming Growth Factor beta | 1 | 2021 | 475 | 0.140 |
Why?
| | Administration, Oral | 9 | 2015 | 851 | 0.130 |
Why?
| | Young Adult | 10 | 2021 | 14122 | 0.130 |
Why?
| | Time Factors | 14 | 2018 | 7140 | 0.130 |
Why?
| | Liver Diseases | 3 | 2011 | 304 | 0.130 |
Why?
| | Algorithms | 5 | 2019 | 1844 | 0.130 |
Why?
| | Blood Coagulation | 2 | 2016 | 268 | 0.130 |
Why?
| | Obesity | 1 | 2011 | 3070 | 0.130 |
Why?
| | Psychometrics | 2 | 2018 | 731 | 0.120 |
Why?
| | Comorbidity | 5 | 2019 | 1652 | 0.120 |
Why?
| | Proportional Hazards Models | 6 | 2022 | 1322 | 0.120 |
Why?
| | Diagnostic Imaging | 1 | 2019 | 341 | 0.120 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2018 | 181 | 0.120 |
Why?
| | B-Lymphocytes | 1 | 2021 | 875 | 0.120 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2024 | 1742 | 0.110 |
Why?
| | Pyridines | 2 | 2015 | 603 | 0.110 |
Why?
| | Iloprost | 2 | 2006 | 45 | 0.110 |
Why?
| | Drug Monitoring | 1 | 2019 | 396 | 0.110 |
Why?
| | Calcium Channel Blockers | 2 | 2024 | 165 | 0.110 |
Why?
| | Pulmonary Edema | 1 | 1995 | 105 | 0.110 |
Why?
| | Tetrazoles | 1 | 2015 | 49 | 0.110 |
Why?
| | Cohort Studies | 7 | 2020 | 5957 | 0.110 |
Why?
| | Graft Rejection | 1 | 1998 | 512 | 0.110 |
Why?
| | Survival Analysis | 8 | 2018 | 1370 | 0.100 |
Why?
| | Hemolysis | 2 | 2014 | 242 | 0.100 |
Why?
| | Models, Theoretical | 2 | 2015 | 578 | 0.100 |
Why?
| | Case-Control Studies | 5 | 2018 | 3603 | 0.100 |
Why?
| | Antibodies, Antinuclear | 1 | 1993 | 62 | 0.100 |
Why?
| | Pilot Projects | 4 | 2010 | 1886 | 0.100 |
Why?
| | Acute Disease | 3 | 2008 | 1029 | 0.100 |
Why?
| | Protein Kinase C | 2 | 1994 | 250 | 0.100 |
Why?
| | Hypothyroidism | 1 | 1993 | 67 | 0.090 |
Why?
| | Societies, Medical | 2 | 2015 | 890 | 0.090 |
Why?
| | Echocardiography, Doppler | 2 | 2014 | 114 | 0.090 |
Why?
| | Pancreatic Neoplasms | 1 | 2021 | 926 | 0.090 |
Why?
| | Colorado | 3 | 2022 | 4558 | 0.090 |
Why?
| | Respiratory Function Tests | 5 | 2018 | 541 | 0.090 |
Why?
| | Exercise | 4 | 2024 | 2183 | 0.090 |
Why?
| | Delphi Technique | 1 | 2014 | 330 | 0.090 |
Why?
| | Endpoint Determination | 2 | 2010 | 84 | 0.090 |
Why?
| | Incidence | 5 | 2015 | 2892 | 0.090 |
Why?
| | Injections, Subcutaneous | 2 | 2023 | 168 | 0.090 |
Why?
| | Pulmonary Circulation | 3 | 2018 | 429 | 0.090 |
Why?
| | Patient Reported Outcome Measures | 1 | 2016 | 496 | 0.090 |
Why?
| | Survival | 1 | 2011 | 38 | 0.090 |
Why?
| | Diagnosis, Differential | 3 | 2020 | 1501 | 0.080 |
Why?
| | Peptidyl-Dipeptidase A | 3 | 2003 | 56 | 0.080 |
Why?
| | Risk Factors | 9 | 2018 | 10796 | 0.080 |
Why?
| | Pain | 2 | 2011 | 785 | 0.080 |
Why?
| | United Kingdom | 3 | 2021 | 337 | 0.080 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 1995 | 387 | 0.080 |
Why?
| | Prevalence | 4 | 2010 | 2839 | 0.080 |
Why?
| | Long-Term Care | 1 | 2011 | 117 | 0.080 |
Why?
| | Reference Values | 2 | 2009 | 794 | 0.080 |
Why?
| | Michigan | 1 | 2010 | 137 | 0.080 |
Why?
| | Respiration, Artificial | 1 | 1995 | 710 | 0.080 |
Why?
| | Animals, Newborn | 5 | 1994 | 890 | 0.080 |
Why?
| | Retrospective Studies | 8 | 2025 | 17149 | 0.080 |
Why?
| | Endothelin-1 | 2 | 2002 | 181 | 0.070 |
Why?
| | Pulmonary Alveoli | 2 | 2005 | 383 | 0.070 |
Why?
| | Guideline Adherence | 2 | 2018 | 586 | 0.070 |
Why?
| | Aldosterone | 1 | 2009 | 42 | 0.070 |
Why?
| | Dinoprostone | 1 | 1989 | 180 | 0.070 |
Why?
| | Elastin | 1 | 1989 | 78 | 0.070 |
Why?
| | Pulmonary Eosinophilia | 1 | 1989 | 26 | 0.070 |
Why?
| | Vasopressins | 1 | 2009 | 60 | 0.070 |
Why?
| | Transaminases | 1 | 2008 | 22 | 0.070 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2009 | 62 | 0.070 |
Why?
| | Vasoconstrictor Agents | 1 | 2009 | 144 | 0.070 |
Why?
| | Renal Insufficiency | 1 | 2010 | 172 | 0.070 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2011 | 392 | 0.070 |
Why?
| | Alveolitis, Extrinsic Allergic | 1 | 1989 | 93 | 0.070 |
Why?
| | Maximum Tolerated Dose | 2 | 2025 | 211 | 0.070 |
Why?
| | Aged, 80 and over | 8 | 2021 | 8284 | 0.070 |
Why?
| | Hospitals, University | 1 | 2008 | 176 | 0.070 |
Why?
| | Multivariate Analysis | 4 | 2015 | 1537 | 0.070 |
Why?
| | Lung Diseases | 2 | 2010 | 781 | 0.070 |
Why?
| | Genetic Predisposition to Disease | 3 | 2018 | 2350 | 0.070 |
Why?
| | Heart Failure | 2 | 2020 | 2324 | 0.070 |
Why?
| | Platelet Aggregation Inhibitors | 3 | 2004 | 496 | 0.060 |
Why?
| | Lupus Erythematosus, Systemic | 3 | 2010 | 238 | 0.060 |
Why?
| | Ventricular Dysfunction, Right | 3 | 2009 | 248 | 0.060 |
Why?
| | Airway Obstruction | 1 | 2009 | 153 | 0.060 |
Why?
| | Drug Utilization | 1 | 2008 | 167 | 0.060 |
Why?
| | Endothelins | 1 | 2007 | 61 | 0.060 |
Why?
| | Hypophosphatemia | 1 | 2006 | 17 | 0.060 |
Why?
| | Drug Costs | 1 | 2008 | 117 | 0.060 |
Why?
| | Hypokalemia | 1 | 2006 | 24 | 0.060 |
Why?
| | Appetite Depressants | 1 | 2006 | 19 | 0.060 |
Why?
| | Clinical Trials as Topic | 2 | 2009 | 1056 | 0.060 |
Why?
| | Autoimmune Diseases | 2 | 2005 | 465 | 0.060 |
Why?
| | Educational Measurement | 1 | 1989 | 325 | 0.060 |
Why?
| | Phosphorus | 1 | 2006 | 98 | 0.060 |
Why?
| | Potassium | 1 | 2006 | 152 | 0.060 |
Why?
| | Ventricular Function | 1 | 2006 | 54 | 0.060 |
Why?
| | 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2005 | 17 | 0.060 |
Why?
| | Telangiectasis | 1 | 2025 | 7 | 0.060 |
Why?
| | Epistaxis | 1 | 2025 | 17 | 0.060 |
Why?
| | Medical Informatics | 1 | 2006 | 96 | 0.060 |
Why?
| | Cattle | 5 | 1994 | 975 | 0.060 |
Why?
| | CREST Syndrome | 2 | 2002 | 6 | 0.060 |
Why?
| | Pleural Diseases | 1 | 2005 | 23 | 0.060 |
Why?
| | Analysis of Variance | 3 | 2009 | 1301 | 0.060 |
Why?
| | Probability | 3 | 2015 | 309 | 0.060 |
Why?
| | Forecasting | 3 | 2021 | 391 | 0.050 |
Why?
| | Immunohistochemistry | 3 | 2005 | 1705 | 0.050 |
Why?
| | Child | 6 | 2011 | 22600 | 0.050 |
Why?
| | Recombinant Proteins | 1 | 2008 | 1363 | 0.050 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2024 | 116 | 0.050 |
Why?
| | Predictive Value of Tests | 3 | 2016 | 2117 | 0.050 |
Why?
| | Arthritis, Rheumatoid | 3 | 2010 | 1170 | 0.050 |
Why?
| | Carbon Monoxide | 2 | 2018 | 82 | 0.050 |
Why?
| | Heterozygote | 1 | 2025 | 313 | 0.050 |
Why?
| | Physicians, Family | 1 | 2005 | 173 | 0.050 |
Why?
| | Age Distribution | 3 | 2010 | 402 | 0.050 |
Why?
| | Sex Distribution | 3 | 2010 | 386 | 0.050 |
Why?
| | Physician's Role | 1 | 2005 | 221 | 0.050 |
Why?
| | Terminology as Topic | 1 | 2005 | 255 | 0.050 |
Why?
| | Neoplasm Metastasis | 1 | 2005 | 691 | 0.050 |
Why?
| | Statistics, Nonparametric | 2 | 2003 | 427 | 0.050 |
Why?
| | Polymyositis | 1 | 2002 | 13 | 0.050 |
Why?
| | Scleroderma, Localized | 1 | 2002 | 11 | 0.050 |
Why?
| | Dermatomyositis | 1 | 2002 | 24 | 0.050 |
Why?
| | Serotonin Antagonists | 1 | 2002 | 30 | 0.050 |
Why?
| | Heart Defects, Congenital | 2 | 2009 | 905 | 0.050 |
Why?
| | Thromboxane-A Synthase | 1 | 2002 | 3 | 0.050 |
Why?
| | Liver Function Tests | 3 | 2011 | 105 | 0.050 |
Why?
| | Enzyme Inhibitors | 2 | 2004 | 820 | 0.050 |
Why?
| | Hypoxia | 3 | 2018 | 1193 | 0.050 |
Why?
| | Polymerase Chain Reaction | 2 | 2003 | 1047 | 0.040 |
Why?
| | Drug Administration Schedule | 4 | 2008 | 779 | 0.040 |
Why?
| | Cardiac Surgical Procedures | 1 | 2008 | 609 | 0.040 |
Why?
| | Signal Transduction | 4 | 2025 | 5185 | 0.040 |
Why?
| | Mutation | 2 | 2025 | 4081 | 0.040 |
Why?
| | Animals | 11 | 2013 | 37948 | 0.040 |
Why?
| | Biomarkers, Pharmacological | 1 | 2021 | 26 | 0.040 |
Why?
| | Cholangiopancreatography, Magnetic Resonance | 1 | 2021 | 24 | 0.040 |
Why?
| | Tricuspid Valve Insufficiency | 2 | 2011 | 24 | 0.040 |
Why?
| | Cardiovascular Agents | 1 | 2023 | 165 | 0.040 |
Why?
| | Clinical Competence | 1 | 1989 | 1237 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2018 | 2137 | 0.040 |
Why?
| | Least-Squares Analysis | 1 | 2021 | 74 | 0.040 |
Why?
| | Injections, Intravenous | 2 | 2013 | 198 | 0.040 |
Why?
| | Adjuvants, Immunologic | 1 | 2002 | 245 | 0.040 |
Why?
| | Multicenter Studies as Topic | 2 | 2006 | 408 | 0.040 |
Why?
| | Tropoelastin | 2 | 1991 | 11 | 0.040 |
Why?
| | Reproductive History | 1 | 2020 | 12 | 0.040 |
Why?
| | Cells, Cultured | 5 | 1994 | 4110 | 0.040 |
Why?
| | Risk | 2 | 2015 | 911 | 0.040 |
Why?
| | Self Report | 1 | 2025 | 869 | 0.040 |
Why?
| | Lymph Nodes | 1 | 2003 | 501 | 0.040 |
Why?
| | Europe | 2 | 2012 | 419 | 0.040 |
Why?
| | Infusion Pumps | 1 | 2000 | 33 | 0.040 |
Why?
| | Jaw | 1 | 2000 | 27 | 0.040 |
Why?
| | Cardiac Output | 1 | 2020 | 179 | 0.040 |
Why?
| | Radiography | 2 | 1995 | 848 | 0.040 |
Why?
| | Genotype | 4 | 2009 | 1847 | 0.040 |
Why?
| | Transplantation, Homologous | 2 | 1998 | 407 | 0.040 |
Why?
| | Delivery of Health Care | 1 | 2006 | 944 | 0.040 |
Why?
| | Autoimmunity | 1 | 2005 | 930 | 0.040 |
Why?
| | Placebos | 2 | 2011 | 193 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2019 | 3414 | 0.040 |
Why?
| | Symptom Assessment | 1 | 2020 | 136 | 0.040 |
Why?
| | Spinal Diseases | 1 | 1999 | 50 | 0.040 |
Why?
| | Intramolecular Oxidoreductases | 1 | 1999 | 65 | 0.040 |
Why?
| | Thrombocytopenia | 1 | 2021 | 202 | 0.040 |
Why?
| | Gonadal Steroid Hormones | 1 | 2020 | 143 | 0.040 |
Why?
| | Genotyping Techniques | 1 | 2018 | 70 | 0.040 |
Why?
| | Lung Diseases, Interstitial | 1 | 2005 | 660 | 0.040 |
Why?
| | Internship and Residency | 1 | 1989 | 1262 | 0.040 |
Why?
| | Uric Acid | 1 | 2000 | 166 | 0.040 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 1999 | 161 | 0.030 |
Why?
| | Methicillin Resistance | 1 | 1998 | 17 | 0.030 |
Why?
| | Plasmapheresis | 1 | 1998 | 24 | 0.030 |
Why?
| | Immunosuppressive Agents | 3 | 1998 | 834 | 0.030 |
Why?
| | Cell Division | 4 | 1994 | 753 | 0.030 |
Why?
| | Pulmonary Diffusing Capacity | 1 | 2018 | 78 | 0.030 |
Why?
| | Hemoptysis | 1 | 1998 | 35 | 0.030 |
Why?
| | Bronchiolitis Obliterans | 1 | 1998 | 61 | 0.030 |
Why?
| | Models, Statistical | 1 | 2022 | 677 | 0.030 |
Why?
| | Cervical Vertebrae | 1 | 1999 | 161 | 0.030 |
Why?
| | Gastrointestinal Diseases | 1 | 2000 | 217 | 0.030 |
Why?
| | alpha 1-Antitrypsin Deficiency | 1 | 1998 | 59 | 0.030 |
Why?
| | Disease-Free Survival | 2 | 2010 | 768 | 0.030 |
Why?
| | Fatal Outcome | 1 | 1998 | 305 | 0.030 |
Why?
| | Biomedical Technology | 1 | 2017 | 49 | 0.030 |
Why?
| | Capillaries | 1 | 1998 | 118 | 0.030 |
Why?
| | Child, Preschool | 2 | 2011 | 11790 | 0.030 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1997 | 42 | 0.030 |
Why?
| | Health Status Indicators | 2 | 2009 | 167 | 0.030 |
Why?
| | Faculty, Medical | 2 | 1990 | 301 | 0.030 |
Why?
| | Myosin Heavy Chains | 1 | 1997 | 183 | 0.030 |
Why?
| | Colonic Diseases | 1 | 1996 | 36 | 0.030 |
Why?
| | Mycoplasma | 1 | 1996 | 5 | 0.030 |
Why?
| | Intestinal Perforation | 1 | 1996 | 46 | 0.030 |
Why?
| | Mycoplasma Infections | 1 | 1996 | 17 | 0.030 |
Why?
| | Blood Coagulation Factors | 1 | 1996 | 60 | 0.030 |
Why?
| | Desensitization, Immunologic | 1 | 1997 | 89 | 0.030 |
Why?
| | Translating | 1 | 2016 | 50 | 0.030 |
Why?
| | Mass Screening | 2 | 2018 | 1348 | 0.030 |
Why?
| | Cardiomyopathy, Dilated | 1 | 1999 | 355 | 0.030 |
Why?
| | Drug Hypersensitivity | 1 | 1997 | 89 | 0.030 |
Why?
| | Myocardium | 2 | 1998 | 928 | 0.030 |
Why?
| | Comparative Effectiveness Research | 1 | 2016 | 167 | 0.030 |
Why?
| | Endothelium, Vascular | 2 | 1994 | 949 | 0.030 |
Why?
| | Dyspnea | 2 | 2008 | 250 | 0.030 |
Why?
| | Pulmonary Emphysema | 1 | 1998 | 275 | 0.030 |
Why?
| | Fibrinolysis | 1 | 1996 | 164 | 0.030 |
Why?
| | Lactobacillus | 1 | 1994 | 28 | 0.030 |
Why?
| | Calibration | 1 | 2015 | 151 | 0.030 |
Why?
| | Recurrence | 1 | 1998 | 1136 | 0.030 |
Why?
| | Tetradecanoylphorbol Acetate | 2 | 1994 | 150 | 0.030 |
Why?
| | Immunization, Passive | 1 | 1994 | 88 | 0.030 |
Why?
| | Drug Approval | 1 | 2015 | 91 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2014 | 2942 | 0.030 |
Why?
| | Antisickling Agents | 1 | 2014 | 7 | 0.030 |
Why?
| | Ferritins | 1 | 2014 | 70 | 0.030 |
Why?
| | South Africa | 1 | 2015 | 265 | 0.030 |
Why?
| | Hydroxyurea | 1 | 2014 | 34 | 0.030 |
Why?
| | Immunoglobulins | 1 | 1994 | 160 | 0.030 |
Why?
| | United States Food and Drug Administration | 1 | 2015 | 205 | 0.030 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 1994 | 70 | 0.030 |
Why?
| | Social Behavior | 1 | 2016 | 287 | 0.020 |
Why?
| | Thyroiditis | 1 | 1993 | 4 | 0.020 |
Why?
| | Raynaud Disease | 1 | 1993 | 3 | 0.020 |
Why?
| | Staphylococcal Infections | 1 | 1998 | 388 | 0.020 |
Why?
| | Cytomegalovirus | 1 | 1994 | 168 | 0.020 |
Why?
| | Genetic Variation | 1 | 2018 | 985 | 0.020 |
Why?
| | Research | 2 | 2009 | 431 | 0.020 |
Why?
| | Cross-Sectional Studies | 3 | 2016 | 5870 | 0.020 |
Why?
| | Pneumonia, Bacterial | 1 | 1994 | 113 | 0.020 |
Why?
| | Administration, Intravenous | 1 | 2014 | 170 | 0.020 |
Why?
| | Focus Groups | 1 | 2016 | 566 | 0.020 |
Why?
| | Immunoenzyme Techniques | 2 | 1994 | 197 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2025 | 2325 | 0.020 |
Why?
| | Enzyme Activation | 2 | 1994 | 762 | 0.020 |
Why?
| | Erythrocyte Indices | 1 | 2012 | 33 | 0.020 |
Why?
| | Blood Flow Velocity | 1 | 2014 | 419 | 0.020 |
Why?
| | Cytomegalovirus Infections | 1 | 1994 | 205 | 0.020 |
Why?
| | Down Syndrome | 1 | 1999 | 522 | 0.020 |
Why?
| | Pulmonary Embolism | 1 | 2015 | 241 | 0.020 |
Why?
| | Creatinine | 1 | 2014 | 509 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2018 | 1374 | 0.020 |
Why?
| | Embolism, Air | 1 | 1992 | 14 | 0.020 |
Why?
| | Erythrocyte Transfusion | 1 | 2014 | 226 | 0.020 |
Why?
| | Cell-Derived Microparticles | 1 | 2012 | 72 | 0.020 |
Why?
| | Chronic Disease | 2 | 2015 | 1810 | 0.020 |
Why?
| | Preoperative Care | 2 | 2009 | 379 | 0.020 |
Why?
| | Cardiomegaly | 2 | 2006 | 174 | 0.020 |
Why?
| | Biomedical Research | 1 | 2017 | 712 | 0.020 |
Why?
| | Homozygote | 1 | 2011 | 200 | 0.020 |
Why?
| | Emotions | 1 | 2016 | 578 | 0.020 |
Why?
| | Thromboxane B2 | 1 | 1989 | 23 | 0.020 |
Why?
| | Calcimycin | 1 | 1989 | 36 | 0.020 |
Why?
| | Mortality | 1 | 2012 | 377 | 0.020 |
Why?
| | Phenotype | 3 | 2010 | 3147 | 0.020 |
Why?
| | Decision Support Techniques | 1 | 2014 | 461 | 0.020 |
Why?
| | Nitric Oxide | 1 | 1994 | 894 | 0.020 |
Why?
| | Drug Synergism | 1 | 1990 | 352 | 0.020 |
Why?
| | Mental Health | 1 | 2016 | 792 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2012 | 638 | 0.020 |
Why?
| | Angiopoietin-1 | 1 | 2009 | 12 | 0.020 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2009 | 23 | 0.020 |
Why?
| | Health Policy | 1 | 2012 | 398 | 0.020 |
Why?
| | Receptors, Retinoic Acid | 1 | 2009 | 42 | 0.020 |
Why?
| | Aromatase | 1 | 2009 | 32 | 0.020 |
Why?
| | Spironolactone | 1 | 2009 | 39 | 0.020 |
Why?
| | Nucleic Acid Hybridization | 1 | 1989 | 186 | 0.020 |
Why?
| | Health Care Costs | 1 | 2012 | 425 | 0.020 |
Why?
| | Dyspepsia | 1 | 2008 | 11 | 0.020 |
Why?
| | Fellowships and Scholarships | 2 | 1990 | 355 | 0.020 |
Why?
| | Pulmonary Veins | 1 | 1989 | 104 | 0.020 |
Why?
| | Hepatitis, Autoimmune | 1 | 2008 | 13 | 0.020 |
Why?
| | California | 1 | 2010 | 471 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 1990 | 1046 | 0.020 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2009 | 68 | 0.020 |
Why?
| | Qualitative Research | 1 | 2016 | 1668 | 0.020 |
Why?
| | Vital Capacity | 1 | 2009 | 290 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2009 | 331 | 0.020 |
Why?
| | Vibrio Infections | 1 | 1987 | 2 | 0.020 |
Why?
| | Echocardiography, Transesophageal | 1 | 2009 | 132 | 0.020 |
Why?
| | Down-Regulation | 1 | 1990 | 616 | 0.020 |
Why?
| | Cystic Fibrosis | 1 | 1998 | 1166 | 0.020 |
Why?
| | Forced Expiratory Volume | 1 | 2009 | 448 | 0.020 |
Why?
| | Cognition | 1 | 2016 | 1263 | 0.020 |
Why?
| | Calcium-Binding Proteins | 1 | 2009 | 222 | 0.020 |
Why?
| | Estrogen Receptor alpha | 1 | 2009 | 151 | 0.020 |
Why?
| | Headache | 1 | 2008 | 151 | 0.020 |
Why?
| | American Heart Association | 1 | 2009 | 356 | 0.020 |
Why?
| | Endocarditis, Bacterial | 1 | 1987 | 46 | 0.020 |
Why?
| | Aminorex | 1 | 2006 | 2 | 0.020 |
Why?
| | RNA, Messenger | 2 | 1997 | 2815 | 0.010 |
Why?
| | Heart Rate | 1 | 2010 | 853 | 0.010 |
Why?
| | Odds Ratio | 1 | 2009 | 1076 | 0.010 |
Why?
| | Protein Biosynthesis | 1 | 1989 | 455 | 0.010 |
Why?
| | Alleles | 1 | 2009 | 886 | 0.010 |
Why?
| | Hypoventilation | 1 | 1985 | 17 | 0.010 |
Why?
| | Hepatitis C | 1 | 2008 | 254 | 0.010 |
Why?
| | Estradiol | 1 | 2009 | 507 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 2005 | 184 | 0.010 |
Why?
| | Statistics as Topic | 1 | 2006 | 284 | 0.010 |
Why?
| | Gene Expression Regulation | 2 | 1997 | 2591 | 0.010 |
Why?
| | Magnesium | 1 | 1985 | 155 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 3 | 2006 | 3888 | 0.010 |
Why?
| | Pancreatic Elastase | 1 | 2004 | 53 | 0.010 |
Why?
| | Drug Prescriptions | 1 | 2006 | 283 | 0.010 |
Why?
| | Hypotension | 1 | 1985 | 126 | 0.010 |
Why?
| | Fibroblasts | 1 | 1989 | 1019 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2009 | 1995 | 0.010 |
Why?
| | Aging | 1 | 1994 | 1938 | 0.010 |
Why?
| | Potassium Channels | 1 | 2004 | 145 | 0.010 |
Why?
| | Logistic Models | 1 | 2009 | 2114 | 0.010 |
Why?
| | DNA | 1 | 1990 | 1447 | 0.010 |
Why?
| | Tablets | 1 | 2003 | 41 | 0.010 |
Why?
| | Critical Care | 1 | 1989 | 695 | 0.010 |
Why?
| | Arginine | 1 | 2004 | 238 | 0.010 |
Why?
| | Research Design | 1 | 2009 | 1129 | 0.010 |
Why?
| | Angiotensin II | 1 | 2003 | 95 | 0.010 |
Why?
| | Sex Factors | 1 | 2008 | 2104 | 0.010 |
Why?
| | Rats | 2 | 2004 | 5570 | 0.010 |
Why?
| | Attitude of Health Personnel | 1 | 2010 | 1180 | 0.010 |
Why?
| | Liver Transplantation | 1 | 2009 | 826 | 0.010 |
Why?
| | Sepsis | 1 | 1987 | 643 | 0.010 |
Why?
| | Heart Ventricles | 1 | 2006 | 751 | 0.010 |
Why?
| | Practice Patterns, Physicians' | 1 | 2010 | 1360 | 0.010 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2004 | 438 | 0.010 |
Why?
| | Colorimetry | 1 | 2000 | 12 | 0.010 |
Why?
| | Spinal Osteophytosis | 1 | 1999 | 3 | 0.010 |
Why?
| | Spinal Cord Compression | 1 | 1999 | 22 | 0.010 |
Why?
| | Ovarian Neoplasms | 1 | 2005 | 589 | 0.010 |
Why?
| | Spinal Stenosis | 1 | 1999 | 31 | 0.010 |
Why?
| | Veins | 1 | 1999 | 69 | 0.010 |
Why?
| | Heart Atria | 1 | 2000 | 141 | 0.010 |
Why?
| | In Situ Hybridization | 1 | 1999 | 318 | 0.010 |
Why?
| | Calcium-Transporting ATPases | 1 | 1997 | 33 | 0.010 |
Why?
| | Atrial Natriuretic Factor | 1 | 1997 | 55 | 0.010 |
Why?
| | Arteries | 1 | 1999 | 258 | 0.010 |
Why?
| | Heart-Lung Transplantation | 1 | 1997 | 13 | 0.010 |
Why?
| | Receptors, Adrenergic, beta | 1 | 1997 | 58 | 0.010 |
Why?
| | Tissue Distribution | 1 | 1997 | 335 | 0.010 |
Why?
| | Liver Cirrhosis | 1 | 1999 | 287 | 0.010 |
Why?
| | Blotting, Western | 1 | 1999 | 1161 | 0.010 |
Why?
| | Systole | 1 | 1997 | 177 | 0.010 |
Why?
| | Diverticulitis, Colonic | 1 | 1996 | 10 | 0.010 |
Why?
| | Spinal Cord | 1 | 1999 | 384 | 0.010 |
Why?
| | Models, Biological | 1 | 2004 | 1811 | 0.010 |
Why?
| | von Willebrand Factor | 1 | 1996 | 85 | 0.010 |
Why?
| | Respiration | 1 | 1996 | 206 | 0.010 |
Why?
| | Physical Fitness | 1 | 1997 | 207 | 0.010 |
Why?
| | Proteins | 2 | 1992 | 1016 | 0.010 |
Why?
| | Ventricular Function, Left | 1 | 1999 | 536 | 0.010 |
Why?
| | Cilazapril | 1 | 1995 | 1 | 0.010 |
Why?
| | Electrophoresis, Agar Gel | 1 | 1995 | 25 | 0.010 |
Why?
| | Thymidine | 1 | 1994 | 60 | 0.010 |
Why?
| | Ganciclovir | 1 | 1994 | 53 | 0.010 |
Why?
| | Subcellular Fractions | 1 | 1994 | 73 | 0.010 |
Why?
| | Opportunistic Infections | 1 | 1994 | 46 | 0.010 |
Why?
| | Lung Diseases, Obstructive | 1 | 1994 | 43 | 0.010 |
Why?
| | Image Processing, Computer-Assisted | 1 | 1999 | 779 | 0.010 |
Why?
| | Acyclovir | 1 | 1994 | 96 | 0.010 |
Why?
| | Blood | 1 | 1994 | 106 | 0.010 |
Why?
| | Tissue Donors | 1 | 1997 | 413 | 0.010 |
Why?
| | Vimentin | 1 | 1994 | 54 | 0.010 |
Why?
| | Immunoglobulins, Intravenous | 1 | 1994 | 133 | 0.010 |
Why?
| | Viremia | 1 | 1994 | 159 | 0.010 |
Why?
| | Factor VIII | 1 | 1994 | 105 | 0.010 |
Why?
| | Gene Expression | 1 | 1998 | 1476 | 0.010 |
Why?
| | Liver | 1 | 2002 | 1889 | 0.010 |
Why?
| | Administration, Inhalation | 1 | 1994 | 570 | 0.010 |
Why?
| | Immunocompromised Host | 1 | 1994 | 202 | 0.010 |
Why?
| | Sputum | 1 | 1994 | 308 | 0.010 |
Why?
| | Neovascularization, Pathologic | 1 | 1994 | 284 | 0.010 |
Why?
| | Lymph | 1 | 1992 | 31 | 0.010 |
Why?
| | Blotting, Northern | 1 | 1991 | 203 | 0.010 |
Why?
| | Flow Cytometry | 1 | 1994 | 1154 | 0.010 |
Why?
| | Extracellular Matrix Proteins | 1 | 1991 | 156 | 0.000 |
Why?
| | Antibodies, Viral | 1 | 1994 | 672 | 0.000 |
Why?
| | Research Support as Topic | 1 | 1990 | 79 | 0.000 |
Why?
| | Financing, Government | 1 | 1990 | 52 | 0.000 |
Why?
| | Career Mobility | 1 | 1990 | 70 | 0.000 |
Why?
| | National Institutes of Health (U.S.) | 1 | 1990 | 143 | 0.000 |
Why?
| | Pneumonia, Viral | 1 | 1994 | 387 | 0.000 |
Why?
| | Rats, Sprague-Dawley | 1 | 1995 | 2521 | 0.000 |
Why?
| | Sheep | 1 | 1992 | 880 | 0.000 |
Why?
| | Tomography, X-Ray Computed | 1 | 1999 | 2754 | 0.000 |
Why?
| | Vibrio | 1 | 1987 | 4 | 0.000 |
Why?
| | Hepatitis, Alcoholic | 1 | 1987 | 16 | 0.000 |
Why?
| | Citrates | 1 | 1985 | 40 | 0.000 |
Why?
| | Protein Binding | 1 | 1992 | 2243 | 0.000 |
Why?
| | Kidney Function Tests | 1 | 1985 | 156 | 0.000 |
Why?
| | RNA | 1 | 1991 | 926 | 0.000 |
Why?
| | Postoperative Complications | 1 | 1997 | 2950 | 0.000 |
Why?
| | Disease Models, Animal | 1 | 1995 | 4539 | 0.000 |
Why?
| | HIV Infections | 1 | 1999 | 3148 | 0.000 |
Why?
| | Anti-Bacterial Agents | 1 | 1994 | 1928 | 0.000 |
Why?
| | Infant | 1 | 1994 | 10023 | 0.000 |
Why?
|
|
Badesch's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|